Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 11, 2014, Pages 7672-7680

  Li, Dengfeng ^a   Jian, Wei ^a   Wei, Chuankui ^a   Song, Hongming ^a   Gu, Yifan ^b   Luo, Yi ^b   Fang, Lin ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Jiao Tong University School of Medicine   (China)

Author keywords

CYLD; MiR 181b inhibitor; Thyroid papillary cancer

Indexed keywords

CYLD PROTEIN, HUMAN; MICRORNA; MIRN181 MICRORNA, HUMAN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PAPILLARY CARCINOMA; PATHOLOGY; THYROID GLAND; THYROID TUMOR; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; THYROID GLAND; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84919493132     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol 2011; 5: 51-6.
2. Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck 2011; 33: 1052-9.
3. Lin X, Guan H, Li H, Liu L, Liu J, Wei G, Huang Z, Liao Z, Li Y. miR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma. Biomed Rep 2014; 2: 122-126.
4. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94: 776-80.
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
6. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010; 12: 201.
7. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012; 6: 590-610.
8. Chen L, Yang Q, Kong WQ, Liu T, Liu M, Li X and Tang H. MicroRNA-181b targets cAMP responds ive element binding protein 1 in gastric adenocarcinomas. IUBMB Life 2012; 64: 628-635.
9. Visone R, Veronese A, Balatti V and Croce CM. MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget 2012; 3: 195-202.
10. Xia Y, Gao Y. MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun 2014; 447: 446-51.
11. Yang L, Wang YL, Liu S, Zhang PP, Chen Z, Liu M, Tang H. miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells. FEBS Lett 2014; 588: 124-30.
12. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M, Croce CM, Fusco A. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006; 13: 497-508.
13. Schwertheim S, Sheu SY, Worm K, Grabellus F, Schmid KW. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res 2009; 41: 475-81.
14. Karin M. NF-kB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009; 1: a000141.
15. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184-99.
16. Li X, Abdel-Mageed AB, Mondal D, Kandil E. The nuclear factor k-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid 2012; 23: 209-18.
17. Song L, Lin C, Gong H, Wang C, Liu L, Wu J, Tao S, Hu B, Cheng SY, Li M, Li J. miR-486 sustains NF-kB activity by disrupting multiple NF-?B-negative feedback loops. Cell Res 2013; 23: 274-89.
18. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39: 493-506.
19. Zhang J, Kong X, Li J, Luo Q, Li X, Shen L, Chen L, Fang L. miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer. Oncol Rep 2014; 31: 1357-63.
20. Takiuchi D, Eguchi H, Nagano H, Iwagami Y, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, Marubashi S, Tanemura M, Mori M, Doki Y. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology 2013; 13: 517-23.
21. Li J, Kong X, Zhang J, Luo Q, Li X, Fang L. MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer. Cancer Cell Int 2013; 13: 7.
22. Li J, Li X, Kong X, Luo Q, Zhang J, Fang L. MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer. Int J Clin Exp Med 2014; 7: 558-65.
23. Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K, Yamashita S, Yamamoto Y, Li JD, Iwase H, Ando Y. Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat 2014; 143: 447-57.